182 research outputs found
Effects of Gabaergic phenols on phospholipid bilayers as evaluated by 1H-NMR
The phenols propofol and thymol, and lately carvacrol, eugenol and chlorothymol, have been shown to act as positive allosteric modulators on GABAA receptor, which is the main inhibitory receptor of the central nervous system. GABAA receptor is an intrinsic membrane protein which activity may be affected by surface-active compounds and by physical changes in the membrane. Recently, we demonstrated that these phenols interacted with the lipid membrane phase, suggesting their anesthetic activity could be the combined result of their specific (with receptor proteins) as well as nonspecific (with surrounding lipid molecules) interaction modulating the supramolecular organization of the receptor environment. In the current study, by using 1H-NMR spectroscopy, we have investigated the effects of the insertion and the possible preferential location of the five phenol derivatives with GABAergic activity on EPC membranes. The results indicate that all compounds are able to insert in EPC phospholipid vesicles and to locate in the region between the polar group (choline molecule), the glycerol and the first atoms of the acyl chains, being the more lipophilic compounds (propofol and chlorothymol) that seem to prefer a deeper bilayer insertion. The location of the phenol molecules would reduce the repulsive forces among phospholipids head groups allowing closer molecular packing and finally diminishing the mobility of the hydrocarbon chains, as revealed by 1H spin relaxation times.Fil: Reiner, Gabriela de Las Nieves. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Investigaciones Biológicas y Tecnológicas. Universidad Nacional de Córdoba. Facultad de Ciencias Exactas, Físicas y Naturales. Instituto de Investigaciones Biológicas y Tecnológicas; Argentina. Universidade Estadual de Campinas; Brasil. Universidade Estadual Paulista Julio de Mesquita Filho; BrasilFil: Fraceto, Leonardo Fernandes. Universidade Estadual Paulista Julio de Mesquita Filho; BrasilFil: Paula, Eneida de. Universidade Estadual de Campinas; BrasilFil: Perillo, Maria Angelica. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Investigaciones Biológicas y Tecnológicas. Universidad Nacional de Córdoba. Facultad de Ciencias Exactas, Físicas y Naturales. Instituto de Investigaciones Biológicas y Tecnológicas; ArgentinaFil: Garcia, Daniel Asmed. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Investigaciones Biológicas y Tecnológicas. Universidad Nacional de Córdoba. Facultad de Ciencias Exactas, Físicas y Naturales. Instituto de Investigaciones Biológicas y Tecnológicas; Argentin
Local anesthetics: interaction with human erythrocyte membranes as studied by ¹H and 31P nuclear magnetic resonance
The literature carries many theories about the mechanism of action of local anesthetics (LA). We can highlight those focusing the direct effect of LA on the sodium channel protein and the ones that consider the interaction of anesthetic molecules with the lipid membrane phase. The interaction between local anesthetics and human erythrocyte membranes has been studied by ¹H and 31P nuclear magnetic resonance spectroscopy. It was found that lidocaine (LDC) and benzocaine (BZC) bind to the membranes, increase the mobility of the protons of the phospholipid's acyl chains, and decrease the mobility and/or change the structure of the polar head groups. The results indicate that lidocaine molecules are inserted across the polar and liquid interface of the membrane, establishing both electrostatic (charged form) and hydrophobic (neutral form) interactions. Benzocaine locates itself a little deeper in the bilayer, between the interfacial glycerol region and the hydrophobic core. These changes in mobility or conformation of membrane lipids could affect the Na+-channel protein insertion in the bilayer, stabilizing it in the inactivated state, thus causing anesthesia.6671Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq
Preparation of the orgamomodified cellulose acetate membranes for adsorption of the ions Cu(II), Cd(II), Mn(II) AND Ni(II)
Cellulose acetate polymeric membranes had been prepared by a procedure of two steps, combining the method of phase inversion and the technique of hydrolysis-deposition. The first step was the preparation of the membrane, and together was organomodified with tetraethylortosilicate and 3-aminopropyltrietoxysilane. Parameters that exert influence in the complexation of the metallic ion, as pH, time of complexation, metal concentration, had been studied in laboratory using tests of metal removal. The membranes had presented resistance mechanics and reactivity to cations, being able to be an alternative for the removal, daily pay-concentration or in the study of the lability of metals complexed
Validation of analytical methodology by HPLC for quantification of bupivacaine (S75-R25) in poli-lactide-co-glicolide nanospheres
Bupivacaine (S75-R25, NovaBupi®) is an amide type local anesthetic widely used. The present work consists of the development and validation of analytical methodology for evaluation of NovaBupi® content in the poly-lactide-co-glycolide nanospheres (PLGA-NS) by high performance liquid chromatography. The separation was made using the reversed-phase column LC-18, acetonitrile/phosphate buffer 85:15 v/v as mobile phase and detection at 220 nm. The results obtained show that the analytical methodology is accurate, reproducible, robust and linear over the concentration range 10-220.0 g/mL of NovaBupi®. The method was applied to determine the encapsulation efficiency and evaluate the release profile of NovaBupi®, showing good results.21522155Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq
Validação de metodologia analítica por cromatografia líquida de alta eficiência para quantificação de bupivacaína (S75-R25) em nanoesferas de poli(lactídeo-co-glicolídeo)
Bupivacaine (S75-R25, NovaBupi®) is an amide type local anesthetic widely used. The present work consists of the development and validation of analytical methodology for evaluation of NovaBupi® content in the poly-lactide-co-glycolide nanospheres (PLGA-NS) by high performance liquid chromatography. The separation was made using the reversed-phase column LC-18, acetonitrile/phosphate buffer 85:15 v/v as mobile phase and detection at 220 nm. The results obtained show that the analytical methodology is accurate, reproducible, robust and linear over the concentration range 10-220.0 g/mL of NovaBupi®. The method was applied to determine the encapsulation efficiency and evaluate the release profile of NovaBupi®, showing good results
Pharmacokinetic profile of liposome-encapsulated ropivacaine after maxillary infiltration anaesthesia
The aim of this study was to determine the pharmacokinetic parameters of liposomal ropivacaine after dental anesthesia in 14 healthy volunteers. In this randomized, double-blind and crossover study, the volunteers received maxillary infiltration of liposome-encapsulated 0.5% ropivacaine and, 0.5% ropivacaine with 1:200,000 epinephrine in two different sessions. Blood samples were collected before and after (from 15 to 1440 min) the administration of either ropivacaine formulation. HPLC with UV detection was used to quantify plasma ropivacaine concentrations. The pharmacokinetic parameters AUC(0-24) (area under the plasma concentration x time curve from baseline to 24 h), AUC(0-infinity) (area under the plasma concentration-time curve from baseline to infinity), C-max (maximum drug concentration), CL (renal clearance), T-max (maximum drug concentration time), t(1/2) (elimination half-life) and Vd (volume of distribution) were analyzed using the Wilcoxon signed-rank test. No differences (p > 0.05) were observed between both formulations for any of the pharmacokinetic parameters evaluated and plasma ropivacaine concentrations, considering each period of time. Both formulations showed similar pharmacokinetic profiles, indicating that the liposomal formulation could be a safer option for use of this local anesthetic, due to the absence of a vasoconstrictor
Physico-chemical characterization of inclusion complex between hydroxymethylnitrofurazone and hydroxypropyl-beta-cyclodextrin
Hydroxymethylnitrofurazone (NFOH) is a prodrug that is active against Trypanosoma cruzi. It however presents low solubility and high toxicity. Hydroxypropyl-beta-cyclodextrin (HP-beta-CD) can be used as a drug-delivery system for NFOH modifying its physico-chemical properties. The aim of this work is to characterize the inclusion complex between NFOH and HP-beta-CD. The rate of NFOH release decreases after complexation and thermodynamic parameters from the solubility isotherm studies revealed that a stable complex is formed (deltaGº= 1.7 kJ/mol). This study focuses on the physico-chemical characterization of a drug-delivery formulation that comes out as a potentially new therapeutic option for Chagas disease treatment.FAPESPCoordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES
Drug-delivery systems for racemic bupivacaine (S50-R50) and bupivacaine enantiomeric mixture (S75-R25): cyclodextrins complexation effects on sciatic nerve blockade in mice
BACKGROUND AND OBJECTIVES: Bupivacaine-induced side effects have led to the search for new local anesthetics (LA) with similar potency and lower toxicity, such as bupivacaine enantiomeric mixture (S75-R25). Drug-delivery systems for LA in carriers, such as cyclodextrins (CD), have been developed to improve anesthetic potency and therapeutic index of those drugs. This study aimed at preparing, characterizing and evaluating the anesthetic efficacy of inclusion complexes of bupivacaine enantiomeric mixture (S75-R25) and racemic bupivacaine (S50-R50) with hydroxypropylb- cyclodextrin (HPb-CD) comparing them to clinically available preparations. METHODS: Inclusion complexes were obtained by mixing appropriate volumes of HPb-CD and S50-R50 or S75-R25 to final 1:1 or 1:2 molar ratios and were characterized by phase solubility experiments. Affinity constants (K) were determined between HPb-CD and each LA. Motor and sensory blocks induced by plain or complexed LA formulations were evaluated in mice by sciatic nerve block. Three LA concentrations were used during the experiment: 0.125, 0.25 and 0.5%. RESULTS: Solubility experiments results were indicative of S50-R50:HPb-CD and S75-R25:HPb-CD complexation, with similar affinity constant (K) values: 14.7 M-1 and 14,3 M-1, respectively. In vivo experiments have shown that complexation has enhanced differential nerve blockade induced by LA: i) motor blockade duration induced by S75-R25 was similar, to the induced by but less intense S50-R50 ( p < 0.001). S50-R50HPb-CD and S75-R25HPb-CD complexes have decreased onset (p < 0.01 and p < 0.05, respectively), without changing motor block intensity (Emax) as compared to plain drugs; ii) sensory block evaluation has revealed higher analgesic intensity with S50-R50HPb-CD (2-fold, p < 0.001) and S75-R25HPb-CD (1.5-1.8-fold, p < 0.01 and p < 0.001, respectively) with both molar ratios (1:1 and 1:2, LA:CD), in addition to prolonging analgesic effect as compared to S50-R50 and S75-R25. CONCLUSIONS: More pronounced analgesic effects obtained by complexation with HPb-CD have shown that both formulations, S50-R50HPb-CD and S75-R25HPb-CD, are very useful for postoperative pain relief, requiring lower LA concentrations. Nevertheless, it is worth noticing that S75-R25 - being less toxic than racemic bupivacaine - is an interesting alternative for the development of more effective and safe drug-delivery systems as compared to racemic bupivacaine (S50-R50).JUSTIFICATIVA E OBJETIVOS: Os efeitos adversos associados ao uso de bupivacaína levaram à procura por novos anestésicos locais (AL) com perfil de bloqueio semelhante e menos tóxicos, surgindo novas preparações como a mistura enantiomérica de bupivacaína (S75-R25). Os sistemas de liberação controlada, contendo AL em carreadores como ciclodextrinas (CD), têm como objetivo melhorar a eficácia anestésica e o índice terapêutico dessas drogas. Este estudo visou a preparação, a caracterização e a avaliação da eficácia anestésica dos complexos de inclusão da mistura enantiomérica da bupivacaína (S75-R25) e da bupivacaína racêmica (S50-R50) com hidroxipropilb-ciclodextrina (HPb-CD) comparando-os com as preparações atualmente utilizadas na clínica. MÉTODO: Os complexos de inclusão foram preparados misturando-se quantidades apropriadas de HPb-CD e S50-R50 ou S75-R25 nas razões molares (1:1 e 1:2) e caracterizados por estudos de solubilidade de fases. Determinaram-se as constantes de afinidade (K) de cada AL pela HPb-CD. Os bloqueios motor e sensorial induzidos pelas drogas livres e complexadas foram avaliados, em camundongos, através do bloqueio do nervo ciático. Para a realização dos experimentos, utilizaram-se três concentrações de AL: 0,125%; 0,25% e 0,5%. RESULTADOS: Os estudos de solubilidade indicaram a formação de complexos de inclusão de S50-R50 e S75-R25 com HPb-CD, com valores de constante de afinidade (K) similares para os dois anestésicos: 14,7 M-1 (S50-R50:HP-bCD) e 14,3 M-1 (S75-R25:HP-bCD). Os testes em animais mostraram que a complexação potencializou o bloqueio nervoso diferencial induzido pelos AL: i) a duração do bloqueio motor induzido por S75-R25 foi similar à do S50-R50, mas menos intenso (p < 0,001). Já os complexos, S50-R50HPb-CD e S75-R25HPb-CD reduziram a latência (p < 0,01 e p < 0,05, respectivamente) sem modificar a intensidade do bloqueio motor (Emáx), em relação às drogas livres; ii) a avaliação do bloqueio sensorial mostrou aumento na intensidade da analgesia com os sistemas S50-R50HPb-CD (2 vezes, p < 0,001) e S75-R25HPb-CD (1,5-1,8 vezes; p < 0,01 e p < 0,001, respectivamente), nas duas proporções molares (1:1 e 1:2, AL:CD), além do prolongamento da duração do efeito analgésico, quando comparados às formulações S50-R50 e S75-R25. CONCLUSÕES: Os efeitos analgésicos mais pronunciados, obtidos após a complexação com HPb-CD, mostram que ambas as formulações, S50-R50HPb-CD e S75-R25HPb-CD, são de grande interesse para o alívio da dor no período pós-operatório, com a vantagem de serem administradas em menores concentrações. Entretanto, há que se ressaltar que a mistura enantiomérica de bupivacaína (S75-R25), por ser menos tóxica, representa uma alternativa no desenvolvimento de formulações de liberação controlada mais seguras e eficazes do que com a bupivacaína racêmica (S50-R50).JUSTIFICATIVA Y OBJETIVOS: Los efectos adversos asociados al uso de bupivacaína llevaron a la búsqueda por nuevos anestésicos locales (AL) con perfil de bloqueo semejante y menos tóxicos, surgiendo nuevas preparaciones como la mezcla enantiomérica de bupivacaína (S75-R25). Los sistemas de liberación controlada, conteniendo AL en carreadores como ciclodextrinas (CD), tienen como objetivo mejorar la eficacia anestésica y el índice terapéutico de esas drogas. Este estudio visó la preparación, caracterización y evaluación de la eficacia anestésica de los complejos de inclusión de la mezcla enantiomérica de la bupivacaína (S75-R25) y de la bupivacaína racémica (S50-R50) con hidroxipropilb-ciclodextrina (HPb-CD) comparándolos con las preparaciones actualmente utilizadas en la clínica. MÉTODO: Los complejos de inclusión fueron preparados mezclándose cantidades apropiadas de HPb-CD y S50-R50 ó S75-R25 en las razones molares (1:1 y 1:2) y caracterizados por estudios de solubilidad de fases. Se determinaron las constantes de afinidad (K) de cada AL por la HPb-CD. Los bloqueos motor y sensorial inducidos por las drogas libres y complejadas fueron evaluados en ratones, a través del bloqueo del nervio ciático. Para la realización de los experimentos, se utilizaron tres concentraciones de AL: 0,125; 0,25 y 0,5%. RESULTADOS: Los estudios de solubilidad indicaron la formación de complejos de inclusión de S50-R50 y S75-R25 con HPb-CD, con valores de constante de afinidad (K) análogos para los dos anestésicos: 14,7 M-1 (S50-R50: HP-bCD) y 14,3 M-1 (S75-R25: HP-bCD). Las pruebas en animales mostraron que la complejidad potenció el bloqueo nervioso diferencial inducido por los AL: i) la duración del bloqueo motor inducido por S75-R25 fue análogo al del S50-R50, pero menos intenso (p < 0,001). Ya los complejos, S50-R50HPb-CD y S75-R25 HPb-CD redujeron la latencia (p < 0,01 y p < 0,05, respectivamente) sin modificar la intensidad del bloqueo motor (Emáx), con relación a las drogas libres; ii) la evaluación del bloqueo sensorial mostró un aumento en la intensidad de la analgesia con los sistemas S50-R50 HPb-CD (2 veces, p < 0,001) y S75-R25 HPb-CD (1,5-1,8 veces; p < 0,01 y p < 0,001, respectivamente), en las dos proporciones molares (1:1 y 1:2, AL:CD), además del prolongamiento de la duración del efecto analgésico, cuando comparados a las formulaciones S50-R50 y S75-R25. CONCLUSIONES: Los efectos analgésicos más pronunciados logrados después de la complexación con HPb-CD muestran que ambas formulaciones, S50-R50 HPb-CD y S75-R25 HPb-CD, son de grande interés para el alivio del dolor en el período postoperatorio, con la ventaja de ser administradas en menores concentraciones. Mientras, hay que resaltar que la mezcla enantiomérica de bupivacaína (S75-R25), por ser una droga menos tóxica, representa una alternativa en el desarrollo de formulaciones de liberación controlada más seguras y eficaces de que con la bupivacaína racémica (S50-R50).31632
Lipid nanostructured carriers systems for ivermectin and methoprene aiming parasite control
The study of characteristics of nanoscale structures and applications now has great interest of researchers from different areas. In this regard, lipid carriers can improve the bioavailability of drugs and the reduction of possible toxicological effects. Thus, the development of nanostructured systems for the agricultural sector, aimed at combating parasites may reduce extensive damage caused to livestock producers and animal health. This study aimed to prepare and characterize lipid carrier systems, such as Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC), as well as evaluate the potential of cyto and genotoxicity of these systems in order to improve and produce alternatives to the use targeting these compounds in veterinary applications. Lipid nanoparticles had become spherical with an average size of 250 nm and remained stable over 120 days. The encapsulation efficiency was greater than 99% for both drugs and release tests showed a strong interaction between drugs and nanoparticles. Cyto- and genotoxicity tests show that nanoparticles made possible changes in cellular viability of the tested cells. Thus, the results showed that the nanoparticles had good colloidal characteristics without changes in its characteristics, enabling the development of carrier systems for these drugs , aiming veterinary applications39910341043FUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULO - FAPESP#2013/12322-2; #2015/15617-9; #2013/24788-
15d-PGJ(2)-loaded solid lipid nanoparticles: physicochemical characterization and evaluation of pharmacological effects on inflammation
FAPESP - FUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULOCNPQ - CONSELHO NACIONAL DE DESENVOLVIMENTO CIENTÍFICO E TECNOLÓGICO15-deoxy-Delta(12,14)-prostaglandin J(2) (15d-PGJ(2)), a peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonist, has physiological properties including pronounced anti-inflammatory activity, though it binds strongly to serum albumin. The use of solid lipid nanoparticles (SLN) can improve therapeutic properties increasing drug efficiency and availability. 15d-PGJ(2)-SLN was therefore developed and investigated in terms of its immunomodulatory potential. 15d-PGJ(2)-SLN and unloaded SLN were physicochemically characterized and experiments in vivo were performed. Animals were pretreated with 15d-PGJ(2)-SLN at concentrations of 3, 10 or 30 mu g.kg(-1) before inflammatory stimulus with carrageenan (Cg), lipopolysaccharide (LPS) or mBSA (immune response). Interleukins (IL-1 beta, IL-10 and IL-17) levels were also evaluated in exudates. The 15d-PGJ(2)-SLN system showed good colloidal parameters and encapsulation efficiency of 96%. The results showed that the formulation was stable for up to 120 days with low hemolytic effects. The 15d-PGJ(2)-SLN formulation was able to reduce neutrophil migration in three inflammation models tested using low concentrations of 15d-PGJ(2). Additionally, 15d-PGJ(2)-SLN increased IL-10 levels and reduced IL-1 beta as well as IL-17 in peritoneal fluid. The new 15d-PGJ(2)-SLN formulation highlights perspectives of a potent anti-inflammatory system using low concentrations of 15d-PGJ(2).15-deoxy-Delta(12,14)-prostaglandin J(2) (15d-PGJ(2)), a peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonist, has physiological properties including pronounced anti-inflammatory activity, though it binds strongly to serum albumin. The use of solid lipid nanoparticles (SLN) can improve therapeutic properties increasing drug efficiency and availability. 15d-PGJ(2)-SLN was therefore developed and investigated in terms of its immunomodulatory potential. 15d-PGJ(2)-SLN and unloaded SLN were physicochemically characterized and experiments in vivo were performed. Animals were pretreated with 15d-PGJ(2)-SLN at concentrations of 3, 10 or 30 mu g.kg(-1) before inflammatory stimulus with carrageenan (Cg), lipopolysaccharide (LPS) or mBSA (immune response). Interleukins (IL-1 beta, IL-10 and IL-17) levels were also evaluated in exudates. The 15d-PGJ(2)-SLN system showed good colloidal parameters and encapsulation efficiency of 96%. The results showed that the formulation was stable for up to 120 days with low hemolytic effects. The 15d-PGJ(2)-SLN formulation was able to reduce neutrophil migration in three inflammation models tested using low concentrations of 15d-PGJ(2). Additionally, 15d-PGJ(2)-SLN increased IL-10 levels and reduced IL-1 beta as well as IL-17 in peritoneal fluid. The new 15d-PGJ(2)-SLN formulation highlights perspectives of a potent anti-inflammatory system using low concentrations of 15d-PGJ(2)118e0161796FAPESP - FUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULOCNPQ - CONSELHO NACIONAL DE DESENVOLVIMENTO CIENTÍFICO E TECNOLÓGICOFAPESP - FUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULOCNPQ - CONSELHO NACIONAL DE DESENVOLVIMENTO CIENTÍFICO E TECNOLÓGICO2014/11016-8303555/2013-
- …